Jean M. Tersak
Expertise in
17
conditions
Expertise in
17
conditions
4401 Penn Avenue, 
Pittsburgh, PA 

Overview

Jean M. Tersak, MD, provides care for pediatric oncology patients and long term survivors of childhood cancer at UPMC Children’s Hospital of Pittsburgh. Dr. Tersak is institutional principal investigator for the UPMC Children’s Oncology Group and director of clinical oncology research within the Division of Pediatric Hematology/Oncology. She is also a professor of pediatrics and clinical and translational science at the University of Pittsburgh School of Medicine and is board-certified in pediatric hematology/oncology.Dr. Tersak earned her bachelor's degree, master’s degree, and  medical degree from the University of Pittsburgh. She completed her residency and fellowship at UPMC Children’s Hospital of Pittsburgh.Dr. Tersak is extensively involved in clinical research including the evaluation and treatment of patients with new diagnosis. Her research interests include the late effects, quality of life, and neurocognitive outcomes in survivors of childhood cancer and evaluation and treatment of opsoclonus myoclonus in patients with neuroblastoma. She is a member of the American Society of Clinical Oncology Children’s Oncology Group.View the full list of Dr. Tersak’s publications on PubMed.

Dr. Tersak is highly rated in 17 conditions, according to our data. Her top areas of expertise are Neuroepithelioma, Neuroblastoma, Reticulohistiocytoma, Histiocytosis, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 14 peer reviewed articles and participating in 63 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

University Of Pittsburgh School Of Medicine

Residency

University of Pittsburgh School of Medicine

Specialties

Pediatric Hematology Oncology

Licenses

Specialist in PA

Board Certifications

American Board Of Pediatrics

Fellowships

University of Pittsburgh School of Medicine

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
View 7 Less Insurance Carriers -

Locations

Pediatric Hematology Oncology in Lawrenceville
4401 Penn Avenue, Pittsburgh, PA 15224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


61 Clinical Trials

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
Neuroblastoma Biology Studies
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Key Adverse Events After Childhood Cancer
View 49 Less Clinical Trials
Similar Doctors
Cheryl A. Hillery
Expertise in
6
conditions
Pediatric Hematology Oncology
Expertise in
6
conditions
Pediatric Hematology Oncology

Pediatric Hematology Oncology In Lawrenceville

4401 Penn Avenue, 
Pittsburgh, PA 
 (0.1 miles away)
Languages Spoken:
English
Accepting New Patients

Cheryl A. Hillery, MD, is clinical director of Hematology at UPMC Children’s Hospital of Pittsburgh and a professor of Pediatrics within the Division of Hematology-Oncology at the University of Pittsburgh School of Medicine. She is the director of the Pediatric Comprehensive Sickle Cell Program and has led basic, translational, and clinical research studies focused on sickle cell disease. Dr. Hillery is highly rated in 6 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia.

Frederico Xavier
Expertise in
5
conditions
Pediatric Hematology Oncology
Expertise in
5
conditions
Pediatric Hematology Oncology

Pediatric Hematology Oncology In Lawrenceville

4401 Penn Avenue, 
Pittsburgh, PA 
 (0.1 miles away)
Languages Spoken:
English, Portuguese, Spanish
Accepting New Patients
Offers Telehealth

Frederico Xavier, MD, MS, is the associate clinical director for the Hemophilia Center of Western Pennsylvania and an associate professor of Pediatrics at the University of Pittsburgh School of Medicine. He is board-certified in Pediatrics and in Pediatric Hematology/Oncology.Dr. Xavier completed his medical degree, pediatric residency, and fellowship training in Brazil. He then completed a pediatric residency in New York, pediatric hematology and oncology fellowship at St. Jude Children’s Hospital, and then a pediatric hemostasis fellowship at the Hospital for Sick Children in Toronto, Ontario, Canada. Dr. Xavier completed a master’s degree in clinical research at the Indiana University-Purdue University Indianapolis.He has published peer-reviewed articles and book chapters in the field of pediatric hemostasis and is currently awarded with a research grant to study inflammation in Hemophilia. Dr. Xavier also sits in the Newborn Screening and Follow-up Technical Advisory Board for the Pennsylvania Department of Health.Dr. Xavier also practices at the Hemophilia Center of Western Pennsylvania, a state and federally-funded 501(c)3 charitable organization that provides comprehensive medical care to the residents of Western Pennsylvania with hemophilia and other bleeding and clotting disorders. The functions of the center include diagnosis and evaluation of individuals with bleeding disorders; treatment of bleeding episodes and complications; education of the patient and family, the community, and other medical providers; communication and advocacy; supervision of home care; and research and data collection.View the full list of Dr. Xavier’s publications on PubMed. Dr. Xavier is highly rated in 5 conditions, according to our data. His top areas of expertise are Hemophilia A, Hemophilic Arthropathy, Hemophilia B, and Von Willebrand Disease (VWD).

James Cooper
Expertise in
2
conditions
Pediatric Hematology Oncology
Expertise in
2
conditions
Pediatric Hematology Oncology

Pediatric Hematology Oncology In Lawrenceville

4401 Penn Avenue, 
Pittsburgh, PA 
 (0.1 miles away)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

James Cooper, MD, MSc, is clinical director of the Coagulation Program at UPMC Children's Hospital of Pittsburgh. He is also an assistant professor of pediatrics at the University of Pittsburgh School of Medicine. He is board certified in pediatric hematology-oncology and pediatrics.Dr. Cooper earned his medical degree from University of Connecticut School of Medicine. He completed a residency and internship in pediatrics at the University of Connecticut-Connecticut Children's Medical Center followed by a fellowship in pediatric hematology-oncology at UPMC Children's Hospital. Dr. Cooper also earned his master's of science in clinical research at the University of Pittsburgh Institute for Clinical Research Education.In his role as clinical director of the Coagulation Program, Dr. Cooper cares for children with bleeding disorders and thrombosis concerns. As part of that mission, Dr. Cooper and Dr. Tahniat Syed of Adolescent Medicine co-lead a dedicated clinic for young women with menstrual disorders, known as the CHAMP (Comprehensive Hematologic Assessment of Adolescents with Menstrual Problems) Clinic. In addition to coagulation disorders, Dr. Cooper also cares for children with a variety of oncologic and other hematologic problems.Dr. Cooper’s research interests include thrombosis rates in adolescents and young adults versus younger children with cancer and the cost effectiveness of laboratory analysis of clotting disorders in children. He is a member of the American Society of Pediatric Hematology and Oncology, the American Society of Hematology, the Children’s Oncology Group, the Critical Mass Young Adult Alliance, the American Thrombosis & Hemostasis Network, the American Academy of Pediatrics, the Foundation for Women and Girls with Bleeding Disorders, and the Hemostasis and Thrombosis Research Society.View the full list of Dr. Cooper’s publications on PubMed. Dr. Cooper is highly rated in 2 conditions, according to our data. His top areas of expertise are Mesenteric Venous Thrombosis, Venous Thromboembolism (VTE), Hemophilia A, and Blood Clots.

Frequently Asked Questions about Dr. Jean M. Tersak

How do I make an appointment with Dr. Jean M. Tersak?

You can book an appointment with Dr. Jean M. Tersak by calling their office at 412-692-5055. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jean M. Tersak a top-rated expert for Neuroepithelioma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jean M. Tersak is classified as an Advanced expert for Neuroepithelioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jean M. Tersak specialize in?

While Dr. Jean M. Tersak is a Pediatric Hematology Oncology, they have specific expertise in Neuroepithelioma, Neuroblastoma, and Reticulohistiocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Hematology Oncology.

Does Dr. Jean M. Tersak participate in research or clinical trials?

Yes. Dr. Jean M. Tersak has published 14 articles and abstracts on conditions like Neuroepithelioma. You can view a list of Dr. Jean M. Tersak's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jean M. Tersak accept my insurance?

Dr. Jean M. Tersak accepts most major insurance plans, including Aetna and CareSource. We recommend calling the office directly at 412-692-5055 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tersak's expertise for a condition
ConditionClose
      View All 17 Advanced Conditions
      View All 25 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile